Investors were disappointed by continued weakness in companion animal demand and competition in key franchises; Zoetis shares fell 7.9% after earnings. U.S. clinic visits were down 3% year to date, while the company said third-quarter revenue and adjusted net income declined in line with its expectations.
Zoetis shares declined 2.3% following Q2 results that fell short of expectations, primarily due to ongoing deceleration and intensified competitive pressure in the Companion Animal segment and a cautious outlook for the near term.
Zoetis shares dropped 25.5% following earnings as investors reacted to an unexpectedly weak U.S. companion animal segment marked by demand softness, increased price sensitivity, intensified competitive pressures, and lack of market expansion that together pressured revenue and margins.
Zoetis delivered solid third-quarter results with a 4% revenue increase and a 9% rise in adjusted net income, showcasing resilience through a diverse product portfolio despite facing macroeconomic headwinds.